Nanovista’s first product, CF800, is a liposome nanoparticle-based imaging agent that:

• Helps cancer surgeons clearly identify tumor boundaries prior to and during surgery for a more complete removal of tumor tissue while preserving healthy tissue
• Holds a strong scientific basis and demonstrated performance in animal studies
• Contains components that are FDA-approved and shown to work with multiple imaging techniques
• Is a long-lasting agent (2 weeks) compared to alternative agents that require multiple injections (minutes or hours)
• Utilizes existing clinical infrastructure and 800nm fluorescence imaging systems, already adopted in most major cancer centres and quickly gaining widespread acceptance in surgical oncology

CF800 (Figure 1) is currently being advanced for Phase I trials.